AR090017A1 - Agonistas de fgfr1 y sus metodos de uso - Google Patents

Agonistas de fgfr1 y sus metodos de uso

Info

Publication number
AR090017A1
AR090017A1 ARP120101715A ARP120101715A AR090017A1 AR 090017 A1 AR090017 A1 AR 090017A1 AR P120101715 A ARP120101715 A AR P120101715A AR P120101715 A ARP120101715 A AR P120101715A AR 090017 A1 AR090017 A1 AR 090017A1
Authority
AR
Argentina
Prior art keywords
methods
fgfr1
agonists
fgfr1 agonists
nucleic acid
Prior art date
Application number
ARP120101715A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR090017A1 publication Critical patent/AR090017A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Agonistas de FGFR1 (factor de crecimiento anti-fibroblastos), incluyendo anticuerpos agonista de anti-FGFR1 y sus métodos de uso. Ácido nucleico, célula huésped, composición farmacéutica, método de tratamiento, método de producción del anticuerpo.
ARP120101715A 2011-05-16 2012-05-15 Agonistas de fgfr1 y sus metodos de uso AR090017A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161486731P 2011-05-16 2011-05-16
US201161536936P 2011-09-20 2011-09-20

Publications (1)

Publication Number Publication Date
AR090017A1 true AR090017A1 (es) 2014-10-15

Family

ID=46124784

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101715A AR090017A1 (es) 2011-05-16 2012-05-15 Agonistas de fgfr1 y sus metodos de uso

Country Status (32)

Country Link
US (6) US9085626B2 (es)
EP (2) EP3219730A1 (es)
JP (2) JP5836481B2 (es)
KR (1) KR101623246B1 (es)
CN (1) CN103596980B (es)
AR (1) AR090017A1 (es)
AU (1) AU2012255881C1 (es)
BR (1) BR112013026266A2 (es)
CA (1) CA2834879C (es)
CL (1) CL2013003296A1 (es)
CO (1) CO6781536A2 (es)
CR (1) CR20130587A (es)
CY (1) CY1119098T1 (es)
DK (1) DK2710035T3 (es)
EA (1) EA030462B1 (es)
EC (1) ECSP13013022A (es)
ES (1) ES2628385T3 (es)
HR (1) HRP20170815T1 (es)
HU (1) HUE033584T2 (es)
IL (1) IL228740A (es)
LT (1) LT2710035T (es)
MX (3) MX339662B (es)
MY (1) MY175338A (es)
PE (1) PE20140995A1 (es)
PL (1) PL2710035T3 (es)
PT (1) PT2710035T (es)
RS (1) RS56090B1 (es)
SG (1) SG194917A1 (es)
SI (1) SI2710035T1 (es)
TW (1) TWI547500B (es)
WO (1) WO2012158704A1 (es)
ZA (1) ZA201307364B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
CA2834879C (en) 2011-05-16 2019-10-22 Genentech, Inc. Fgfr1 agonists and methods of use
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
EP4306165A3 (en) 2011-07-01 2024-04-17 NGM Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
LT3495367T (lt) 2012-06-13 2021-02-25 Incyte Holdings Corporation Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
EP2925775B1 (en) 2012-11-28 2020-09-16 NGM Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
ES2915851T3 (es) 2012-12-27 2022-06-27 Ngm Biopharmaceuticals Inc Péptidos quiméricos de FGF19 para usar en el tratamiento de trastornos de ácidos biliares
KR20180080342A (ko) * 2013-03-15 2018-07-11 익스프레션 패톨로지, 인크. 암 요법을 지시하는 srm 검정
MY181497A (en) 2013-04-19 2020-12-23 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
NZ718962A (en) 2013-10-28 2019-12-20 Ngm Biopharmaceuticals Inc Cancer models and associated methods
TWI670283B (zh) * 2013-12-23 2019-09-01 美商建南德克公司 抗體及使用方法
BR112016017248A8 (pt) 2014-01-24 2018-04-17 Ngm Biopharmaceuticals Inc anticorpo ou fragmento seu, agente de ligação, animal transgênico, hibridoma, vetor, composição farmacêutica, método de indução de sinalização de semelhantes a fgf19 e/ou fgf21, método para ativar um complexo klotho beta/receptor de fgf, método para melhorar o metabolismo da glicose em um indivíduo, método de detecção da presença de klotho beta, uso do anticorpo ou fragmento seu, uso da composição farmacêutica, método de tratamento e método para melhorar parâmetros metabólicos
AU2015236073B2 (en) * 2014-03-25 2020-04-30 Regeneron Pharmaceuticals, Inc. FGF21 receptor agonists and uses thereof
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
AU2015277438B2 (en) 2014-06-16 2020-02-27 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
JP6949711B2 (ja) 2014-10-23 2021-10-20 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド ペプチドバリアントを含む医薬組成物及びその使用方法
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
WO2016134320A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3070103A1 (en) * 2015-03-19 2016-09-21 Institut Hospitalier Universitaire De Strasbourg Anti-Claudin 1 monoclonal antibodies for the prevention and treatment of hepatocellular carcinoma
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
JP6940479B2 (ja) 2015-08-03 2021-09-29 ノバルティス アーゲー Ｆｇｆ２１関連障害を処置する方法
CN108026175A (zh) * 2015-09-24 2018-05-11 豪夫迈·罗氏有限公司 用于治疗癫痫的方法
EP3371217A1 (en) 2015-11-08 2018-09-12 H. Hoffnabb-La Roche Ag Methods of screening for multispecific antibodies
EP3888672A1 (en) 2015-11-09 2021-10-06 NGM Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
CN105273063B (zh) * 2015-11-30 2018-06-12 中国人民解放军第三军医大学第三附属医院 调节fgfr1活性的多肽及其应用
CN108602890A (zh) 2015-12-11 2018-09-28 瑞泽恩制药公司 用于减少或预防对egfr和/或erbb3阻滞剂具有抗性的肿瘤生长的方法
CN106317226B (zh) 2016-08-19 2017-09-05 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
WO2018032638A1 (zh) 2016-08-19 2018-02-22 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
US11370841B2 (en) 2016-08-26 2022-06-28 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
US10759850B2 (en) 2016-11-01 2020-09-01 Berg Llc Filamin A binding proteins and uses thereof
WO2018095932A1 (en) 2016-11-22 2018-05-31 Merck Patent Gmbh Monoclonal antibody directed to fgfr1
MX2019009498A (es) 2017-02-08 2019-10-02 Novartis Ag Anticuerpos mimeticos de fgf21 y usos de los mismos.
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
EP3788046A1 (en) 2018-05-04 2021-03-10 Incyte Corporation Salts of an fgfr inhibitor
MA52494A (fr) 2018-05-04 2021-03-10 Incyte Corp Formes solides d'un inhibiteur de fgfr et leurs procédés de préparation
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4045151A1 (en) 2019-10-14 2022-08-24 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
BR112023022878A2 (pt) 2021-05-04 2024-01-23 Regeneron Pharma Agonistas do receptor fgf21 multiespecíficos e seus usos
TW202313611A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
JP3095175B2 (ja) 1992-11-13 2000-10-03 アイデック ファーマシューティカルズ コーポレイション Ｂ細胞リンパ腫の治療のためのヒトｂリンパ球限定分化抗原に対するキメラ抗体と放射能標識抗体の療法利用
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO1998058964A1 (en) 1997-06-24 1998-12-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
IL136544A0 (en) 1997-12-05 2001-06-14 Scripps Research Inst Humanization of murine antibody
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1141024B1 (en) 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
DK2270150T4 (da) 1999-04-09 2019-08-26 Kyowa Hakko Kirin Co Ltd Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle.
FR2796073B1 (fr) * 1999-07-07 2003-08-29 Centre Nat Rech Scient Anticorps anti-idiotypiques des facteurs de croissance des fibroblastes et leur utilisation comme medicaments
MXPA02003456A (es) 1999-10-04 2002-10-23 Medicago Inc Metodo para regular la transcripcion de genes foraneos.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CA2388245C (en) 1999-10-19 2012-01-10 Tatsuya Ogawa The use of serum-free adapted rat cells for producing heterologous polypeptides
EP1240319A1 (en) 1999-12-15 2002-09-18 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
CA2395660A1 (en) 1999-12-29 2001-07-12 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
AU2001252940A1 (en) * 2000-03-22 2001-10-03 Amgen Inc. Fibroblast growth factor receptor-like molecules and uses thereof
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
KR100865801B1 (ko) 2000-08-29 2008-10-28 제넨테크, 인크. 암 치료의 효능을 증진시키는 방법
EP1666600B1 (en) 2000-08-29 2009-12-30 Genentech, Inc. Methods for enhancing the efficacy of cancer therapy
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
PL218428B1 (pl) 2000-10-06 2014-12-31 Kyowa Hakko Kogyo Kk Komórka, sposoby wytwarzania przeciwciał, leki zawierające przeciwciała, komórka CHO i przeciwciało klasy IgG
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
KR20100018071A (ko) 2001-08-03 2010-02-16 글리카트 바이오테크놀로지 아게 항체 의존적 세포 독성이 증가된 항체 글리코실화 변이체
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
AU2003205716B2 (en) * 2002-01-31 2008-08-21 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. FGFR agonists
JPWO2003084569A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物含有医薬
US7749753B2 (en) 2002-04-09 2010-07-06 Kyowa Hakko Kirin Co., Ltd Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
JPWO2003085118A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物の製造方法
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
CA2481657A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
NZ556507A (en) 2002-06-03 2010-03-26 Genentech Inc Synthetic antibody phage libraries
US20050282733A1 (en) 2002-06-27 2005-12-22 Prins Johannes B Differentiation modulating agents and uses therefor
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
ES2347241T3 (es) 2002-12-16 2010-10-27 Genentech, Inc. Variantes de inmunoglobulina y sus utilizaciones.
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP1688439A4 (en) 2003-10-08 2007-12-19 Kyowa Hakko Kogyo Kk HYBRID PROTEIN COMPOSITION
AU2004280065A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
ATE506077T1 (de) * 2003-10-16 2011-05-15 Imclone Llc Fibroblasten-wachstumsfaktor-1-hemmer und behandlungsverfahren dafür
JP2005170923A (ja) 2003-10-21 2005-06-30 Konica Minolta Medical & Graphic Inc リポソーム含有ｘ線造影剤およびその製造方法
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
ES2697327T3 (es) 2003-11-06 2019-01-23 Seattle Genetics Inc Compuesto intermedio para la preparación de conjugados que comprenden derivados de auristatina y un enlazador
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
CA2550245A1 (en) * 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
SG172616A1 (en) 2004-04-13 2011-07-28 Hoffmann La Roche Anti-p-selectin antibodies
WO2006028714A1 (en) 2004-09-02 2006-03-16 Eli Lilly And Company Muteins of fibroblast growth factor 21
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
JP4948413B2 (ja) 2004-09-23 2012-06-06 ジェネンテック， インコーポレイテッド システイン操作抗体および結合体
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006065582A2 (en) 2004-12-14 2006-06-22 Eli Lilly And Company Muteins of fibroblast growth factor 21
WO2006130527A2 (en) * 2005-05-31 2006-12-07 Novartis Ag Mutations and polymorphisms of fibroblast growth factor receptor 1
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
DK2059533T3 (da) 2006-08-30 2013-02-25 Genentech Inc Multispecifikke antistoffer
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
WO2008123625A1 (ja) * 2007-04-06 2008-10-16 National Institute Of Advanced Industrial Science And Technology 補助因子による受容体の活性化方法並びにリガンド活性の利用方法
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
EP2165715B1 (en) * 2007-05-29 2013-12-18 Sapporo Medical University Therapeutic agent for cancer, and method for treatment of cancer
DK2235064T3 (en) 2008-01-07 2016-01-11 Amgen Inc A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
PE20120021A1 (es) 2008-10-10 2012-02-10 Amgen Inc Mutantes fgf21
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
CA2834879C (en) 2011-05-16 2019-10-22 Genentech, Inc. Fgfr1 agonists and methods of use

Also Published As

Publication number Publication date
BR112013026266A2 (pt) 2020-11-10
LT2710035T (lt) 2017-06-26
US20150376283A1 (en) 2015-12-31
MY175338A (en) 2020-06-19
WO2012158704A1 (en) 2012-11-22
HRP20170815T1 (hr) 2017-08-25
ECSP13013022A (es) 2014-01-31
EP2710035A1 (en) 2014-03-26
US20180100018A1 (en) 2018-04-12
CN103596980B (zh) 2017-08-08
AU2012255881B2 (en) 2015-08-13
CA2834879C (en) 2019-10-22
IL228740A (en) 2017-04-30
CO6781536A2 (es) 2013-10-31
KR101623246B1 (ko) 2016-05-20
CY1119098T1 (el) 2018-02-14
AU2012255881C1 (en) 2015-11-26
PT2710035T (pt) 2017-06-05
US20200140557A1 (en) 2020-05-07
KR20140012150A (ko) 2014-01-29
SG194917A1 (en) 2013-12-30
EA201391540A1 (ru) 2014-03-31
IL228740A0 (en) 2013-12-31
MX370233B (es) 2019-12-06
EP3219730A1 (en) 2017-09-20
ES2628385T3 (es) 2017-08-02
CR20130587A (es) 2013-12-09
PE20140995A1 (es) 2014-08-23
TWI547500B (zh) 2016-09-01
MX2019014654A (es) 2020-02-07
NZ616206A (en) 2015-04-24
PL2710035T3 (pl) 2017-09-29
RS56090B1 (sr) 2017-10-31
DK2710035T3 (en) 2017-06-19
EA030462B1 (ru) 2018-08-31
JP2016029084A (ja) 2016-03-03
US9085626B2 (en) 2015-07-21
US20240076388A1 (en) 2024-03-07
CA2834879A1 (en) 2012-11-22
US9845359B2 (en) 2017-12-19
AU2012255881A1 (en) 2013-11-21
HUE033584T2 (hu) 2017-12-28
CN103596980A (zh) 2014-02-19
EP2710035B1 (en) 2017-04-12
JP2014523866A (ja) 2014-09-18
JP5836481B2 (ja) 2015-12-24
TW201300411A (zh) 2013-01-01
SI2710035T1 (sl) 2017-07-31
US20210087283A1 (en) 2021-03-25
CL2013003296A1 (es) 2014-07-25
MX339662B (es) 2016-06-03
MX2013013291A (es) 2013-12-02
US20120294861A1 (en) 2012-11-22
ZA201307364B (en) 2015-01-28

Similar Documents

Publication Publication Date Title
AR090017A1 (es) Agonistas de fgfr1 y sus metodos de uso
AR091098A1 (es) ANTICUERPOS E INMUNOCONJUGADOS CONTRA Ly6E Y METODOS DE USO
AR088322A1 (es) Anticuerpos anti-htra1 y metodos de uso
AR095774A1 (es) Anticuerpos anti-il-4 y anticuerpos biespecíficos y sus usos
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
AR099465A1 (es) Anticuerpos anti-jagged1 y métodos de uso
BR112015007120A2 (pt) anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo
AR093446A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
AR103161A1 (es) Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
BR112015001592A8 (pt) análise de imagem e medidas de amostras biológicas
BR112016010706A2 (pt) anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, sequência de ácido nucleico, vetor de expressão, célula hospedeira e método de produção de um anticorpo
EA201590488A1 (ru) Способы модификации клеток-хозяев
BR112014012624A2 (pt) anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
AR089752A1 (es) Anticuerpos anti-lrp5 y metodos de uso
EA201600252A1 (ru) Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
EA201490815A1 (ru) Составы этанерцепта, стабилизированные с помощью аминокислот
AR080873A1 (es) Anticuerpos contra factor de crecimiento epidermico (anti-erbb3 o anti-her3)
BR112013021134A2 (pt) moduladores e métodos de uso
MX2019003427A (es) Composiciones para cultivo celular y metodos para la produccion de polipeptidos.
BR112016008477A2 (pt) Corpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo
MX2015011781A (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
BR112015003032A8 (pt) anticorpos isolados,ácidos nucleico isolados,célula hospedeira,método de produzir um anticorpo,imunoconjugado,formulação famacêutica,uso do anticorpo e método de tratamento de um indivíduo.

Legal Events

Date Code Title Description
FB Suspension of granting procedure